PTC-Guided Therapy for Peritoneal Mesothelioma

Inclusion Criteria: Patients must meet ALL of the following criteria to be eligible for the study: * Aged 18 years or older. * Histopathologically confirmed diagnosis of epithelioid or biphasic malignant peritoneal mesothelioma (MPM). * Scheduled to undergo cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) and subsequent adjuvant therapy. * Availability of sufficient fresh tumor tissue sample obtained during surgery for Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing. * Karnofsky Performance Status (KPS) score \> 60. * Adequate hematologic function: * White blood cell count ≥ 3.5 × 10⁹/L * Platelet count ≥ 80 × 10⁹/L * Adequate hepatic function: * Total bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) \< 2 × upper limit of normal (ULN) * Adequate renal function: * Serum creatinine \< 1.2 × ULN * Adequate cardiac and pulmonary function to tolerate major surgery, as assessed by the investigator. * Voluntarily agrees to participate by providing written informed consent and demonstrates good compliance. Exclusion Criteria: Patients who meet ANY of the following criteria will be excluded from the study: * Presence of concurrent severe medical comorbidities that, in the investigator's judgment, preclude tolerance to the study treatment. * Diagnosis of another active malignant tumor during the screening process, which may interfere with the study outcomes. * Considered by the investigator to be unsuitable for participation in this study for any other reason (e.g., psychological, familial, or social factors). * Unwillingness to accept the assigned treatment regimen or the required follow-up schedule.